Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,632 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression, Unipolar Clear all
Completed Phase 1 Interventional Results available

Development of Pregnenolone as a Treatment for Depression

NCT03645096
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Pregnenolone 500 mg, Pregnenolone 800 mg, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 1 Interventional

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression

NCT00961454
View directory record Official record
Conditions
Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions
Photobiomodulation with a super-luminous light emitting diode
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Early Phase 1 Interventional

Feasibility Pilot of Accelerated Stimulation With TMS for Treatment of Major Depressive Disorder (FAST-MDD)

NCT06961851
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
aTMS utilizing the MagVenture TMS device
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 6:58 PM EDT
Active, not recruiting Phase 2 Interventional

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT05774665
View directory record Official record
Conditions
Treatment Resistant Depression, Inflammation, Overweight
Interventions
Omega 3, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 6:58 PM EDT
Not listed Phase 1 Interventional

Ketamine for Major Depressive Disorder

NCT03721900
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 4 Interventional

Biomarkers for Outcomes In Late-life Depression (BOLD)

NCT01082237
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
62 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

NCT01360645
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Arcadia, California • Beverly Hills, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 3 Interventional

PUFA Augmentation in Treatment of Major Depression

NCT00067301
View directory record Official record
Conditions
Major Depression
Interventions
Polyunsaturated Fatty Acids (PUFA), Citalopram
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 20, 2026, 6:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

NCT06480201
View directory record Official record
Conditions
Healthy, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
21 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder

NCT00629551
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
saredutant (SR48968), paroxetine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 3 Interventional Results available

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

NCT01312922
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
Drug
Lead sponsor
PharmaNeuroBoost N.V.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Glendale, California • National City, California • Riverside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

NCT04669665
View directory record Official record
Conditions
Depressive Disorder, Major, Suicidal
Interventions
SLS-002, Placebo, Standard of care, Intranasal device
Drug · Other · Device
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
21
States / cities
Orange, California • Panorama City, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 4 Interventional

Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

NCT00178100
View directory record Official record
Conditions
Unipolar Depression
Interventions
Interpersonal Psychotherapy, paroxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
69 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 2 Interventional Results available

Lexapro and Pramipexole and to Treat Major Depression

NCT00086307
View directory record Official record
Conditions
Major Depression
Interventions
Pramipexole, Escitalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Not applicable Interventional Results available

Home-based tDCS in Major Depressive Disorder

NCT04799405
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
tDCS
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
50 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Phase 4 Interventional Results available

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

NCT01473394
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Dose-matched placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Beverly Hills, California • Encino, California • New Port Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 20, 2026, 6:58 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2025

NCT07052357
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

NCT00562367
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cytomel (liothyronine)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 22, 2007 · Synced Oct 20, 2026, 6:58 PM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

NCT00449007
View directory record Official record
Conditions
Depression, Alcoholism, Suicidal Behavior
Interventions
fluoxetine, bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Not applicable Interventional Results available

iCBT With TMS in Patients With MDD

NCT05988619
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transcranial Magnetic Stimulation, Internet-Based Cognitive Behavioral Therapy, Psychoeducation
Device · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 6:58 PM EDT
Recruiting Not applicable Interventional

Mindfulness-Based fMRI Neurofeedback for Depression

NCT05617495
View directory record Official record
Conditions
Depression in Adolescence, Rumination
Interventions
Mindfulness + fMRI Neurofeedback
Other
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 6:58 PM EDT
Completed Not applicable Interventional Results available

Genomics Used to Improve DEpression Decisions

NCT02109939
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
GeneSight Psychotropic
Genetic
Lead sponsor
Assurex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
61
States / cities
Birmingham, Alabama • Bellflower, California • Chino, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 20, 2026, 6:58 PM EDT
Not yet recruiting Not applicable Interventional

Sham-Controlled Rapid-Acting Neuromodulation for Depression

NCT07487454
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
intermittent theta burst stimulation, Sham (No Treatment)
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 6:58 PM EDT